Novel Cost-Effective Approaches to the Treatment of Community-Acquired Infections

Abstract

OBJECTIVE

To review approaches to the diagnosis and treatment of patients with community-acquired infections.

INTRODUCTION:

Dramatic changes in the antibiotic susceptibility of pathogens commonly associated with community-acquired infections have occurred during the past decade.

DISCUSSION:

Changes in the antibiotic sensitivity profile of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis that have occurred over the past several years have required modifications in empiric antibiotic selections for infections due to these pathogens. The most profound changes have occurred with S. pneumoniae, which has shown significant resistance to β-lactams by means of alteration of one or more of the five important penicillin-binding proteins. Many of these organisms have become resistant to other classes of antibiotics; some are sensitive only to vancomycin. H. influenzae and M. catarrhalis have developed resistance primarily by production of β-lactamase.

CONCLUSIONS

The antibiotic selection process for the treatment of community-acquired pneumonia relates to the site of infection and, in many cases, the in vitro sensitivity testing results or known patterns in a given geographic area.

Keywords

community-acquired infections cost-effectiveness

Get full access to this article

View all access options for this article.

References

Musher

. Infections caused by Streptococcus pneumoniae: Clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 1992;14:801–9.

Klein

. Otitis media. Clin Infect Dis 1994;19:823–30.

Greiman

Butler

Tenover

Elliott

Facklam

. Emergence of drug resistant pneumococcal infections in the United States. JAMA 1994;271:1831–5.

Physician's desk reference. Montvale, NJ: Medical Economics Co., Inc., 1995.

Jacobs

Appelbaum

. Antibiotic-resistant pneumococci. Rev Med Microbiol 1995;6:77–93.

Hofman

Cetron

Farley

Baughman

Facklam

Elliott

The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1996;333:481–6.

National Committee for Clinical Laboratory Standards. Zone diameter interpretive standards and equivalent minimum inhibitory concentration (MIC) breakpoints for Streptococcus pneumoniae. Villanova, PA: National Committee for Clinical Laboratory Standards, 1994:14.

Haas

Stratton

Griffin

Weeks

Alls

. Diminished activity of ceftizoxime in comparison to cefotaxime and ceftriaxone against Streptococcus pneumoniae. Clin Infect Dis 1995;20:671–6.

Klugman

Capper

Bryskier

. In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrob Agents Chemother 1996;40:2802–24.

10.

Neu

. Otitis media: Antibiotic resistance of causative pathogens and treatment alternatives. Pediatr Infect Dis J 1995;14:551–6.

11.

Quagliarello

Sheld

. Treatment of bacterial meningitis. N Engl J Med 1997;336:708–16.

12.

Friedland

McCracken

Jr.

Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377–82.

13.

Rotschafer

Zabinski

Walker

. Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 1992;12(6 pt 2):64S–70S.

14.

Butler

Breiman

Lipman

Hofman

Facklam

. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: Implications for development of a conjugate vaccine. J Infect Dis 1995;171:885–9.

15.

Dugan

Melamed

Muallen

Piglansky

Greenberg

Abram-Son

Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate of pneumococcal vaccine. J Infect Dis 1996;174:1271–8.